Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Inclusion Criteria:

• Voluntary written informed consent to participate in the study

• Active subfoveal MNV (any subtype) or juxtafoveal/extrafoveal MNV secondary to AMDwith a subfoveal component related to the MNV activity in the study eye as assessedby FA (evidence of leakage) or SD-OCT (presence of fluid) judged by the centralreading center at screening

• BCVA ETDRS letter score of 78 letters to 35 letters in the study eye as measured bythe ETDRS visual acuity chart at screening

• CST ≥ 450 μm at screening

Exclusion Criteria:

• Subretinal hemorrhage, fibrosis, or atrophy of > 50% of the total lesion area and/orthat involves the fovea in the study eye

• Uncontrolled glaucoma in the study eye

• Aphakia or pseudophakia with AC-IOL in the study eye

• Active intraocular inflammation in the study eye

• Any current ocular condition for which visual acuity loss would not improve fromresolution of macular edema in the study eye

• History of rhegmatogenous retinal detachment in the study eye

• Any current or history of ocular disease other than nAMD in the study eye that mayconfound assessment of the macula or affect central vision

• History of the following therapies in the study eye:

• History of vitrectomy surgery, submacular surgery, or other surgicalintervention for AMD

• Prior treatment PDT with Visudyne®, external-beam radiation therapy,transpupillary thermotherapy, or panretinal photocoagulation

• Periocular or intraocular (sub-Tenon or IVT) corticosteroids within 12 weeksprior to Day 1

• Previous intraocular device implantation except PC-IOL

• Previous laser (any type) to the macular area

• Previous treatment with IVT anti-VEGF drugs other than ranibizumab,bevacizumab, aflibercept 2 mg, and their biosimilars;

• Treatment with ranibizumab, bevacizumab, aflibercept 2 mg, or their biosimilarswithin 12 weeks prior to Day 1. Previously treated patients who received thesemedications more than 12 weeks prior to Day 1 can be enrolled, but the patientsshould be diagnosed with nAMD within 3 years prior to Day 1

• Any current or history of endophthalmitis in either eye

• History of idiopathic or autoimmune-associated uveitis in either eye

• Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in eithereye